Profile
Sector:
IndustrialsIndustry:
Specialty Industrial MachineryCountry:
United StatesIPO:
08 May 2008Website:
http://www.enovis.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:21:28 GMTDividend
Analysts recommendations
Institutional Ownership
ENOV Latest News
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller.
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago.
Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com.
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment.
New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024. New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 1(current)
- 2
What type of business is Enovis?
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
What sector is Enovis in?
Enovis is in the Industrials sector
What industry is Enovis in?
Enovis is in the Specialty Industrial Machinery industry
What country is Enovis from?
Enovis is headquartered in United States
When did Enovis go public?
Enovis initial public offering (IPO) was on 08 May 2008
What is Enovis website?
https://www.enovis.com
Is Enovis in the S&P 500?
No, Enovis is not included in the S&P 500 index
Is Enovis in the NASDAQ 100?
No, Enovis is not included in the NASDAQ 100 index
Is Enovis in the Dow Jones?
No, Enovis is not included in the Dow Jones index
When was Enovis the previous earnings report?
No data
When does Enovis earnings report?
The next expected earnings date for Enovis is 06 November 2024